Therefore, the ITI regimen was used to treat patients with AML1-ETO fusion gene–positive AML, and results showed that the total effective rate was 90%, which was higher than that of previously reported data, which might be related to the disease subtypes of the patients, which also suggests that the ITI treatment scheme is more effective in reversing AML1-ETO fusion gene positivity in patients with AML. The gene discussed is RUNX1; the disease is acute myeloid leukemia.